May 29, 2024 – Dr. Marco Infante has been granted with the Extraordinary Ability O1 Visa by the U.S. Citizenship and Immigration Services (USCIS) for Extraordinary Ability in the Sciences.
May 29, 2024 – Dr. Marco Infante has been granted with the Extraordinary Ability O1 Visa by the U.S. Citizenship and Immigration Services (USCIS) for Extraordinary Ability in the Sciences.
October 10, 2024 – Dr. Marco Infante lecture at the 49th Congress of the International Society for the History of Medicine (Salerno, Italy) – “From Aretaeus of Cappadocia to the bioartificial pancreas: retracing the key events in the history of diabetes mellitus”
49th ISHM Congress (October 9-12; Salerno, Italy) – Dr. Marco Infante lecture “From Aretaeus of Cappadocia to the bioartificial pancreas: retracing the key events in the history of diabetes mellitus” Read the article here
August 9, 2023 – Dr. Marco Infante has been elected a Full Member of the Sigma Xi Scientific Research Honor Society in recognition of his significant scientific contributions to the field of diabetes mellitus.

August 9, 2023 – Dr. Marco Infante has been elected a Full Member of the Sigma Xi Scientific Research Honor Society in recognition of his significant scientific contributions to the field of diabetes mellitus. Sigma Xi is one of the oldest and largest interdisciplinary scientific honor societies in the world – founded in 1886 at […]
May 10, 2020 – Dr. Infante has been appointed Distinguished Supervisor for the international Network of Immunity in Infection, Malignancy and Autoimmunity (NIIMA) of the Universal Scientific Education and Research Network (USERN).

May 10, 2020 – Dr. Infante has been appointed Distinguished Supervisor for the international Network of Immunity in Infection, Malignancy and Autoimmunity (NIIMA) of the Universal Scientific Education and Research Network (USERN).
Healio News (June 3, 2020): “Long-term data lacking for Hydroxychloroquine use in Type 2 Diabetes, COVID-19”

Healio News (June 3, 2020): “Long-term data lacking for Hydroxychloroquine use in Type 2 Diabetes, COVID-19” Read the article here
May 27, 2020: Considerations for Hydroxychloroquine Use in Patients with Diabetes Mellitus

May 27, 2020: Considerations for Hydroxychloroquine Use in Patients with Diabetes Mellitus Read the article here
Type 1 diabetes and technological advances: towards the Artificial Pancreas

Interview for “Sanità & Benessere” (February 2021) – “Type 1 diabetes and technological advances: towards the artificial pancreas” Read the article here
Dr. Infante’s contribution to the “Europe and Food Report” by the Barilla Center for Food & Nutrition (BCFN) 2021 – “Towards a Sustainable Prevention of Type 2 Diabetes”

Dr. Infante’s contribution to the “Europe and Food Report” by the Barilla Center for Food & Nutrition (BCFN) 2021 – “Towards a Sustainable Prevention of Type 2 Diabetes” Read the article here
Dr. Infante’s article “Antihyperglycemic properties of hydroxychloroquine in patients with diabetes: Risks and benefits at the time of COVID-19 pandemic” listed among the Top Cited Articles 2020-2021 in Journal of Diabetes (Wiley)

Infante M, Ricordi C, Fabbri A. Antihyperglycemic properties of hydroxychloroquine in patients with diabetes: Risks and benefits at the time of COVID-19 pandemic. J Diabetes. 2020 Sep;12(9):659-667. DOI: 10.1111/1753-0407.13053. Read the article here
Artificial Organs (Wiley) journal dedicates the September 2021 Issue Cover to Dr. Infante’s article entitled “Dual-hormone artificial pancreas for management of type 1 diabetes: Recent progress and future directions” [Artif Organs. 2021 Sep;45(9):968-986]

“Dual-hormone artificial pancreas for management of type 1 diabetes: Recent progress and future directions” by Marco Infante, David A. Baidal, Michael R. Rickels, Andrea Fabbri, Jay S. Skyler, Rodolfo Alejandro and Camillo Ricordi. Artif Organs. 2021 Sep;45(9):968-986. DOI: 10.1111/aor.14023. Read the article here